
Opinion|Videos|February 25, 2025
Comparing Afami-Cel Outcomes With Chemotherapy and Other Treatment Options
A panelist discusses how afamitresgene autoleucel (afami-cel) has shown encouraging response rates and durability of response in a heavily pretreated population where standard chemotherapy typically yields limited benefit, though direct comparisons are challenging because of the lack of randomized trials and the distinct patient populations treated with different therapeutic approaches.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How does afami-cel’s outcomes compare with chemotherapy, other immunotherapies, and investigational agents?
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5

